Drugs & Targets Regeneron, Inovio agree to study glioblastoma combination therapy May 12, 2017Vol.43 No.19
Drugs & Targets FDA grants an accelerated approval for AstraZeneca’s Imfinzi for urothelial carcinoma May 05, 2017Vol.43 No.18
Drugs & Targets Draft Local Coverage Determination favorable to Oncotype DX Genomic Prostate Score May 05, 2017Vol.43 No.18
Drugs & Targets Opdivo gets European approval for squamous cell head and neck cancer May 05, 2017Vol.43 No.18
Drugs & Targets Tecentriq receives accelerated approval as initial treatment for advanced bladder cancer May 01, 2017Vol.40 No.04
Drugs & Targets FDA approves midostaurin combination for AML; Companion diagnostic also approved April 28, 2017Vol.43 No.17
Drugs & Targets FDA expands indications for regorafinib in hepatocellular carcinoma April 28, 2017Vol.43 No.17
Drugs & Targets FDA grants accelerate approval for brigatinib for ALK-positive NSCLC April 28, 2017Vol.43 No.17
Drugs & Targets FDA takes action against 14 companies for selling illegal cancer treatments April 28, 2017Vol.43 No.17
Drugs & Targets DelMar collaborates with Duke to study VAL-083 as front-line GBM treatment April 28, 2017Vol.43 No.17
